摘要
Dear editor,The 2019 novel coronavirus(later renamed as SARS-CoV-2 in February 2020)infected over 12 million people globally by early July 2020,causing mild to severe COVID-19 in millions.Monitoring the levels of antibodies such as immunoglobin(Ig)G,M and A that are specific to SARS-CoV-2 and present in the blood provides not only an alternative method for diagnosing SARS-CoV-2 infection(including asymptomatic carriers),but also a simple way to monitor immune responses in convalescent patients or after vaccination.A high and persistent level of antibodies specific to SARS-CoV-2,especially those that can bind to and neutralize the virus,would be a strong indication that an immunized host could resist to SRAS-CoV-2 infection.Currently,there are no effective drugs to specifically prevent or cure SARS-CoV-2 infection;therefore,host immune responses and antibody-based therapeutics will continue to play important roles in combating and later preventing COVID-19.
基金
T.J.is supported by the Strategic Priority Research Program of the Chinese Academy of Sciences(XDB29030104)
National Natural Science Foundation of China(31870731 and U1732109)
the Fundamental Research Funds for the Central Universities(WK2070000108)
a COVID-19 special task grant supported by Chinese Academy of Sciences Clinical Research Hospital(Hefei)with Grant No.YD2070002017
M.H.is supported by the new medical science fund of University of Science and Technology of China(WK2070000130)
J.W.and X.Y.are supported by the Fundamental Research Funds for the Central Universities with Grant Nos.YD9110004001 and YD9110002002,respectively.
